A collaboration between Seres Therapeutics, Inc., a leading microbiome therapeutics platform company, and Emulate, Inc., a private company commercializing the Organs-on-Chips technology, has formed to advance Emulate’s Intestine-Chip platform, a micro-engineered, living-tissue-based system that models the human intestine.
“Emulate has developed a highly innovative technology platform consisting of multiple human cell types that may be far more accurate in recreating human gastrointestinal tissue and its interaction with the microbiome than conventional cell culture approaches,” said David Cook, Ph.D., Executive Vice President of R&D and Chief Scientific Officer of Seres. “We expect Emulate’s technology platform will enhance our approach for drug discovery and accelerate our efforts to identify promising new microbiome therapeutic candidates for inflammatory bowel disease, other autoimmune or immunological conditions, infectious diseases, and other serious disease states, which may have a microbiome therapeutic based solution.”
“We are extremely pleased to work with Seres, a leader in the development of microbiome therapeutics, and apply our Organs-on-Chips technology to enhance drug discovery in an emerging field, such as the microbiome,” said James Coon, Chief Executive Officer of Emulate. “The microbiome represents a critically important new area of medicine, and our ‘Intestine-Chip’ is remarkably well suited to evaluate complex biological mechanisms, such as the impact of bacterial compositions on the integrity of the gut barrier and mechanisms of healing in response to inflammation.”
Seres intends to use the technology to identify novel bacteria compositions with therapeutic potential.